Editas Medicine Inc. (EDIT)
Editas Medicine Inc. (EDIT) Stock Price, Analysis & Data
| Bid | 2.14 |
| Market Cap | 434.62M |
| Revenue (ttm) | 47.01M |
| Net Income (ttm) | -73.95M |
| Beta | 2.06 |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.76 |
| P/B (ttm) | 4.13 |
| P/S (ttm) | 9.25 |
| Earnings Date | Nov 9, 2026 |
| Ask | 3.69 |
| Volume | 1,064,634 |
| Avg. Volume (20D) | 2,563,858 |
| Open | 2.96 |
| Previous Close | 2.95 |
| Day's Range | 2.82 - 3.02 |
| 52-Week Range | 1.66 - 4.54 |
| Analyst | Buy |
| Price Target | 5 (76.68%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle ce...
Financial Performance
In 2025, Editas Medicine's revenue was 40.52M, an increase of 25.39% compared to the previous year's 32.31M. Earnings were -160.06M, a decrease of -32.49%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for EDIT stock is "Buy". The 12-month stock price forecast is 5, which is upside of 76.68% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
